Save 20% off your first order using our new site with code HELLO! Expires November 30th.

Diabetic retinopathy is the leading cause of blindness in people aged between 20 and 60 years. After 15 years of having diabetes, 98 percent of patients with Type 1 diabetes and 78 percent of patients with Type 2 diabetes have some degree of retinal damage. A recent paper by Maugeri, D’Amico, Bucolo, and D’Agato reports that PACAP-38 has a protective effect on the retinal pigmented epithilium in a model of diabetic retinopathy. The protective effect appears to occur through a EGFR-dependent mechanism. PACAP-38 has also been reported to have neuroprotective effects on devloping rat retina (Silveira, M; et al., J. Biol. Chem.,2002, 227, 16075-80). This peptide has a further effect on eyesight by stimulating tear production and reducing signs of dry eye (Nakamachi, T; et al., Nature Commun., 2016, 7, 12034). Drops containing PACAP-38 increased tear production in mice for up to two hours. The tears were produced in the infraorbital lacrimal gland.

AAPPTec offers PACAP-38 for research applications in 0.5 mg, 1.0 mg and 2.5 mg vials. We can also provide larger quantities. Please contact AAPPTec for a quotation on larger quantities.